BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh E, Khan RJ, Jha RK, Amera GM, Jain M, Singh RP, Muthukumaran J, Singh AK. A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. J Genet Eng Biotechnol 2020;18:69. [PMID: 33141358 DOI: 10.1186/s43141-020-00085-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Swain SS, Panda SK, Luyten W. Phytochemicals against SARS-CoV as potential drug leads. Biomed J 2021;44:74-85. [PMID: 33736953 DOI: 10.1016/j.bj.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Hernández González JE, Eberle RJ, Willbold D, Coronado MA. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease. Front Mol Biosci 2022;8:816166. [DOI: 10.3389/fmolb.2021.816166] [Reference Citation Analysis]
3 El Hassab MA, Ibrahim TM, Shoun AA, Al-rashood ST, Alkahtani HM, Alharbi A, Eskandrani RO, Eldehna WM. In silico identification of potential SARS COV-2 2′- O -methyltransferase inhibitor: fragment-based screening approach and MM-PBSA calculations. RSC Adv 2021;11:16026-33. [DOI: 10.1039/d1ra01809d] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zeng L, Li D, Tong W, Shi T, Ning B. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. Biochem Pharmacol 2021;189:114424. [PMID: 33482149 DOI: 10.1016/j.bcp.2021.114424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
5 Ismail MI, Ragab HM, Bekhit AA, Ibrahim TM. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study. Comput Biol Med 2021;131:104295. [PMID: 33662683 DOI: 10.1016/j.compbiomed.2021.104295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Denesyuk AI, Permyakov SE, Johnson MS, Permyakov EA, Uversky VN, Denessiouk K. Structural leitmotif and functional variations of the structural catalytic core in (chymo)trypsin-like serine/cysteine fold proteinases. Int J Biol Macromol 2021;179:601-9. [PMID: 33713772 DOI: 10.1016/j.ijbiomac.2021.03.042] [Reference Citation Analysis]
7 Singh N, Villoutreix BO. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises. Comput Struct Biotechnol J 2021;19:2537-48. [PMID: 33936562 DOI: 10.1016/j.csbj.2021.04.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ghosh S, Bhattacherjee D, Satpati P, Bhabak KP. Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease. J Biomol Struct Dyn 2021;:1-12. [PMID: 34424151 DOI: 10.1080/07391102.2021.1967786] [Reference Citation Analysis]
9 Ghosh R, Badavath VN, Chowdhuri S, Sen A. Identification of Alkaloids from Terminalia chebula as Potent SARS‐ CoV‐2 Main Protease Inhibitors: An In Silico Perspective. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202200055] [Reference Citation Analysis]
10 Erdogan T. DFT, molecular docking and molecular dynamics simulation studies on some newly introduced natural products for their potential use against SARS-CoV-2. J Mol Struct 2021;1242:130733. [PMID: 34054142 DOI: 10.1016/j.molstruc.2021.130733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Vicidomini C, Roviello V, Roviello GN. In Silico Investigation on the Interaction of Chiral Phytochemicals from Opuntia ficus-indica with SARS-CoV-2 Mpro. Symmetry 2021;13:1041. [DOI: 10.3390/sym13061041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 15.0] [Reference Citation Analysis]
12 Yuce M, Cicek E, Inan T, Dag AB, Kurkcuoglu O, Sungur FA. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins 2021. [PMID: 34169568 DOI: 10.1002/prot.26164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Agrawal PK, Agrawal C, Blunden G. Rutin: A Potential Antiviral for Repurposing as a SARS-CoV-2 Main Protease (M pro ) Inhibitor. Natural Product Communications 2021;16:1934578X2199172. [DOI: 10.1177/1934578x21991723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
14 Rudrapal M, Celik I, Khan J, Ansari MA, Alomary MN, Yadav R, Sharma T, Tallei TE, Pasala PK, Sahoo RK, Khairnar SJ, Bendale AR, Zothantluanga JH, Chetia D, Walode SG. Identification of bioactive molecules from Triphala (Ayurvedic herbal formulation) as potential inhibitors of SARS-CoV-2 main protease (Mpro) through computational investigations. J King Saud Univ Sci 2022;34:101826. [PMID: 35035181 DOI: 10.1016/j.jksus.2022.101826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
15 Denesyuk AI, Permyakov EA, Johnson MS, Permyakov SE, Denessiouk K, Uversky VN. Structural and functional significance of the amino acid differences Val35Thr, Ser46Ala, Asn65Ser, and Ala94Ser in 3C-like proteinases from SARS-CoV-2 and SARS-CoV. Int J Biol Macromol 2021:S0141-8130(21)02441-7. [PMID: 34774600 DOI: 10.1016/j.ijbiomac.2021.11.043] [Reference Citation Analysis]